http://www.kustomerkinetics.com
Kustomer Kinetics, Inc. offers a 100% satisfaction guarantee on all of their products, with a 30 day return policy from receipt of order. If a product does not perform as expected when used as directed, contact our customer service department prior to returning the unused portion for replacement or refund-no questions, no hassle! Kustomer Kinetics, Inc. offers a 100% satisfaction guarantee on all of their products with a 30 day return policy from receipt of order. If a product does not perform as expected when used as directed, contact our customer service department prior to returning the unused portion for replacement or refund-no questions, no hassle!
Xttrium Laboratories Inc. has been a family owned and operated business for the past 70 years. It has seen many changes in that time period but one aspect will always remain the same, our commitment to quality. The companyen Joseph Creevy, an Executive VP of catalogue sales for Spiegel, and a group of physicians decided to open a full service treatment clinic for epilepsy patients. A staff of physicians, technicians, nurses, and pharmacists was formed, and Western Medical, Inc. opened its doors for the first time in the summer of 1932 at 415 W. Pershing Rd innbsp,the Chicago Bridgeport neighborhood. Once patients were stabilized on their medications, monthly prescriptions were mail ordered to the patients doorstep. Thus making, Western Medical one of the first mail order pharmacies in the United States. By the 1940s, Western Medical was treating over 1,000 patients. In 1932, Xttrium Labratories was established to produce an oral medicine with a time release formulation. In 1951, following the death of their father, Joseph Creevyd, took over the reins of both companies. Xttrium began expanding the business through entering the hospital market place with a product line, which included surgical scrub soaps, surgical instrument disinfectants, and several private label projects for a variety of companies. In 1982, Xttrium was awarded New Drug Applications (NDA) for a variety of Chlorhexidine Gluconate products, which became the cornerstone of their business. During the 1980s, Xttrium began to formulate and manufacture CHG based solutions for surgical scrub, and patient prep prior to surgery for major hospital products manufactures across the United States. These companies included Cardinal Health, Becton Dickenson, Sage Products, Purdue Frederick, Steris, Ballard, Medline, and Meritech. By the 1990s, Xttrium became the largest manufacturer of CHG solutions in the U.S. After the death of Robert Creevy in 1995, Kevin Creevy became president of the company and has run the company successfully ever since. In 2000, Xttrium signed a contract with Zila Pharmaceutical to manufacture their prescription oral rinse, Peridex. In 2002, Zila agreed to have Xttrium manufacture and sell the generic version of Peridex. As of 2006, Zila and Xttrium owned a 70%+ market share in the prescription oral rinse market place. Also in 2006, Xttrium will expand their product portfolio with 17 new drug products in the cough and cold category. Xttrium also plans to file 12 Abbreviated New Drug Applications for liquid generic pharmaceuticals and 4 Abbreviated New Drug Applications for solid generic pharmaceuticals in 2006 and 2007. nbsp,Xttrium has a strong growth plan for its future in the generic drug market, but vows to maintain the solid reputation for excellence and quality built in its long history.
Thomson Research Associates (TRA), a Canadian company, develops and markets Ultra-Fresh antimicrobial treatments for textiles and polymers. Ultra-Fresh, a world leader in antibacterial and antifungal treatments, has been a global success since its 1955 introduction. Developed in the TRA laboratories, Ultra-Fresh has found countless applications in the manufacture of textiles, plastics, foams, coatings and rubber-based materials. Wherever it is used Ultra-Fresh diminishes odours, promotes freshness and extends product life by attacking the very source of a universal problem -- bacteria, fungi, and other destructive microorganisms. The benefits of Ultra-Fresh are available to manufacturers around the world through a distributor network that serves North and South America, Europe, Asia, Australia and the Pacific Rim. The TRA laboratories in Toronto specialize in the development and testing of antimicrobial treatments, and have a track record of innovation and success. Their services are freely available worldwide through local Ultra-Fresh distributors. Ultra-Fresh customers around the world display the Ultra-Fresh brand on their products as a guarantee to consumers of excellence in antimicrobial protection. This web site provides useful information about Ultra-Fresh to customers, potential customers and consumers. For assistance on specific issues or applications please contact your local Ultra-Fresh distributor, or TRA. Thank you for visiting Thomson Research Associates. We welcome your comments on this website at info@ultra-fresh.com.
Nexera has teamed up with innovative leaders in the antimicrobial protected specialty textile market to develop a unique one-of-a-kind respirator mask which is proven to protect individuals from infectious disease. In a collaborative effort, and through certain exclusive arrangements, Nexera, Foss Manufacturing, LLC ("Foss") and AgION Technologies, Inc. ("AgION") have integrated several proprietary and patented technologies, to create what is believed to be the world's first and most consistent, reliable and effective antimicrobial respirator mask - The "SpectraShieldâ„¢ Series of antimicrobial N99 respirator and surgical mask.
Alistagen Corporation was founded with the mission to become the world's leading biotechnology company, setting the highest clinical standards for scientists working on the frontiers of healthcare worldwide. With a strong technology base and powerful infrastructure, we create and deliver innovative medical treatments in important areas of healthcare that enable people to live longer, healthier and more active lives. Alistagen applies innovative thinking to the discovery of unique therapies that are based on the synergistic properties of modern science and nature, Alistagen Corporation seeks practical solutions that will have a profound impact on the lives of millions. Our mission is to be the first to introduce innovative concepts in all areas of research and development, to create value for our customers, shareholders, employees and the communities in which we live and work. Alistagen has a diversified portfolio of proprietary pharmaceutical/ healthcare products in various stages of development, including treatments for asthma, allergies, tooth and gum disease, anti-infective respiratory disorders, inflammatory conditions, and immune system disorders. In collaboration with the scientists at University of Missouri - Rolla, Alistagen is currently exploring several of novel compounds with tremendous potential to transform the entire coatings industry. For example, our new preventive and remedial, prophylactic liquid coating(paint) revolutionizes the life sciences, promises new treatments for disease, improves health, and enhances the overall quality of life in a simple, safe and more natural approach to healthcare. To date, Alistagen has developed and commercialized the following Smart coating (paint) product lines: , CaliwelÔ with BNA Antimicrobial Coating: A revolutionary antimicrobial surface coating that has a variety of applications in the architectural interior coating market and is the ideal solution for recurrent mold, mildew, fungi, odor-causing bacteria and algae growth on coating surfaces. , CaliwelÔ HVAC: A ground-breaking anti-microbial surface coating with its application designed for the interior of HVAC ducts, and other areas of HVAC systems, offering a means to inhibit the growth of odor-causing microorganisms on coating surfaces. , CaliwelÔ Industrial Coating: A revolutionary anti-microbial surface coating that can be used inside stud walls, crawl spaces and other hidden areas, offering long-term inhibition of odor-causing microorganisms on coating surfaces.
Frontier Pharmaceutical, Inc. develops, manufactures, markets and licenses active chlorine dioxide based products incorporating the patented DioxiCare® System. Frontier specializes in the topical application of chlorine dioxide, on the body and on hard surfaces. Products are formulated as liquids, gels, pastes and soaps. Uses include: oral care, skin care, wound care and surface treatment. The DioxiCare® System was developed by Howard Alliger, founder of Frontier and pioneer in the chemistry of chlorine dioxide. Mr. Alliger was the first to patent a method (in 1978) of utilizing chlorine dioxide for topical diseases and other "small-scale" applications. Prior to this, chlorine dioxide, which is a gas, was utilized only on a large scale, such as for the treatment of municipal water supplies, and paper pulp bleaching. Mr. Alliger therefore opened the field of chlorine dioxide and made it practical for topical use. The full potential of chlorine dioxide is only now being realized. Our company's goal is to provide quality chlorine dioxide-based products to the consumer, professional and military markets. Given DioxiCare's® diversity, we believe that Frontier's products will become a household name in both the home and work environments.
Founded in 1983 and headquartered in Meriden, CT, Aplicare is a market leader in the formulation, production and packaging of topical antiseptic and personal care products for use in today's professional health care setting. Just recently, we expanded our offering to include sterile procedural kits and trays including the first innovation in procedural kit design in over 30 years.
Symbol Lon Pharmaceuticals, Inc. (Symbollon) is engaged in the development and commercialization of iodine-based pharmaceutical agents and antimicrobials. Symbollon has developed iodine technology that has the potential to maximize the therapeutic index of iodine. The therapeutic index of a drug is the ratio of the largest safe dose to the smallest effective dose. The Company’s technology accomplishes this by controlling the ratio of molecular iodine to the other inactive species of iodine typically present in solution. The Company has concentrated its product development work on the proposed product application for a treatment for fibrocystic breast disease. The Company’s iodine-based technology can be used in a number of product application areas, which can be grouped into women’s healthcare and infection control. (Source: 10KSB)
Chemeq Limited is an Australia-based veterinary pharmaceutical company, in the business of developing, manufacturing and marketing its product, CHEMEQ polymeric anti-microbial (CHEMEQ), for the prevention and control of intestinal bacterial diseases in feedstock animals, such as pigs and poultry. The Company believes that its product, CHEMEQ, has demonstrated in vitro activity against a range of microorganisms, including gram-positive and gram-negative bacteria, bacterial spores, mycobacteria, protozoa, viruses, yeasts and fungi. In addition, it believes that CHEMEQ has the same effectiveness against multiple antibiotic resistant bacteria as non-resistant bacteria, including pathogenic strains of Escherichia coli.
Ash Access Technology, Inc. is an integrated specialty pharmaceutical / medical device company engaged in the development and commercialization of proprietary technologies and devices to treat and prevent the clinical consequences of diseases and disorders related to vascular access. The company has an advanced portfolio of innovative products targeting catheter-related bloodstream infections (CRBSI) and poor patency (blood flow) , the significant challenges associated with the use of both acute and chronic catheters for vascular access. The company was founded in 2003 by Mr. Robert B.Truitt (President & CEO) and Dr. Stephen R. Ash (Chaiman of the Board) in Lafayette, IN. Our research and development programs are led by the expertise and practical experience of Dr. Ash who has been a practicing nephrologist for over 30 years. Dr. Ash is a world-recognized researcher and thought-leader in the field of Nephrology / Interventional Nephrology; patent holder in extracorporeal devices, sorbent chemistry, and vascular / peritoneal access devices; and a founding member of the ASDIN (American Society of Diagnostic & Interventional Nephrology). Our team's comprehensive understanding of vascular access devices, their complications and clinical consequences, combined with the proven ability for product development and commercialization, creates an organization that is well positioned to make a unique and significant impact in the lives of patients suffering from the consequences of vascular access complications. We are building our commercial product portfolio to focus on breakthrough technologies in areas with significant, unmet medical needs: Discovering, formulating, clinical testing and commercializing a novel antimicrobial / antithrombotic therapy (ZuragenÔ) for the prevention and treatment of CRBSI as well as the eradication of biofilm. Building a dynamic hemodialysis and peritoneal dialysis catheter portfolio to include an innovative open / closed lumen tip design and other technological advances which are significant advances over the original Ash Split Cath® (Medcomp®, 1996) design. Pursuing the integration of ZuragenÔ technology with our catheter designs to form a novel eluting device that creates a barrier for infection which would potentially last months instead of days. The commitment to fulfill our mission is also evident by the substantial investment in our ongoing research and development programs, established partnerships with industry leading research organizations as well as our collaboration with thought-leaders and experts in the fields of Nephrology, Interventional Nephrology and Infectious Disease.
Helix BioMedix, Inc. is a biopharmaceutical company with a library of structurally bioactive peptides and patents covering hundreds of thousands of peptide sequences. The Company has developed short, small-chain peptides with anti-infective, anti-inflammatory properties, such as the stimulation of cell proliferation and migration. These peptides are targeted for use as ingredients in cosmetics and topical therapeutics. The applications include anti-aging skin care, acne treatment, wound healing and the treatment of fungal dermatoses. It has developed numerous peptide sequences in the two areas of application, which includes consumer (skin care) and pharmaceutical. The Company has developed a number of peptides capable of stimulating certain aspects of the skin’s innate ability to regenerate and is marketing these peptides as ingredients for cosmetic use. (Source: 10-K)
NUCRYST Pharmaceuticals Corp. develops, manufactures and commercializes medical products that fight infection and inflammation. In addition, the Company’s nanocrystalline silver structures have exhibited potent anti-inflammatory properties in preclinical studies. It produces its nanocrystalline silver as a coating for wound dressing products under the trademark SILCRYST and as a powder for use in medical devices and as an active pharmaceutical ingredient (API). The Company is a majority owned subsidiary of The Westaim Corporation (Westaim). (Source: 10-K)
Best known for its flagship product, Bayer Aspirin, Bayer Corporation produces a broad range of healthcare, crop protection, polymer and chemical products that help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability and improve people's lives. Bayer Pharmaceuticals is a division of Bayer Health Care and a member of the worldwide Bayer Group, a $27 billion international healthcare and chemicals group based in Leverkusen, Germany. The Bayer Group stock is a component of the DAX and is listed on the New York Stock Exchange (ticker symbol: BAY).
Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News, one of the Top 20 Employers (Science) and ranked the No. 1 Company to Sell For (Selling Power). In previous years, Roche has been named as a Top Company for Older Workers (AARP) and one of the Best Companies to Work For in America (Fortune).
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory